EA Perez

E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer

Lori J. Goldstein, Anne O’Neill, JA Sparano et al. · Journal of Clinical Oncology · 2005 · 67 citations

Medicine, Oncology, Pharmacology +17

Clinical Benefit Rate and Time to Response in RIBBON-1, a Randomized, Double-Blind, Phase III Trial of Chemotherapy with or without Bevacizumab (B) for the First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC).

Nicholas J. Robert, Véronique Dièras, John A. Glaspy et al. · Cancer Research · 2009 · 35 citations

Medicine, Oncology, Pharmacology +15

kappa-Immunoglobulin corneal deposits associated with monoclonal gammopathy. Immunohistochemical and electron microscopic findings.

Graichen Df, EA Perez, Jones Db et al. · PubMed · 1994 · 15 citations

Medicine, Ophthalmology, Pathology +16

A phase I trial of weekly combination KOS-862 (Epothilone D) and trastuzumab in HER-2 overexpressing malignancies

Javier Cortés, José A. Martinez‐Climent, P. Gómez et al. · Journal of Clinical Oncology · 2006 · 14 citations

Medicine, Oncology, Pharmacology +14